TY - JOUR
T1 - Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry
AU - Oosterhaven, Jart A F
AU - Spekhorst, Lotte S
AU - Zhang, Junfen
AU - Voorberg, Angelique N
AU - Romeijn, Geertruida L E
AU - Boesjes, Celeste M
AU - de Graaf, Marlies
AU - de Bruin-Weller, Marjolein S
AU - Schuttelaar, Marie L A
N1 - Funding Information:
Marjolein S. de Bruin-Weller has been a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme, and UCB. Marie L. A. Schuttelaar: Sanofi Genzyme, Pfizer, LEO Pharma, Eli Lilly – advisory board member; AbbVie, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme – investigator; Regeneron Pharmaceuticals, Inc. – consultant; Sanofi Genzyme, Novartis – research grant. Marlies de Graaf has been an advisory board member and/or speaker for Sanofi-Genzyme, Eli Lilly and Leo Pharma. The other authors report no conflict of interest.
Publisher Copyright:
© 2021 The Author(s). Published with license by Taylor and Francis Group, LLC.
PY - 2022/6
Y1 - 2022/6
N2 - BACKGROUND: Eczema control is a new construct to be measured in atopic dermatitis (AD).OBJECTIVES: Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 and 52 weeks.METHODS: Cross-sectional questionnaire study. Patients from the Dutch BioDay registry completed the Atopic Dermatitis Control Test (ADCT), Recap of Atopic Eczema (RECAP) and Treatment Satisfaction Questionnaire for Medication, Version II (TSQM v. II), along with other Patient Reported Outcome Measures (PROMs).RESULTS: 104/157 patients responded (response rate 66.2%). Median ADCT score was 4 (interquartile range [IQR] 5); median RECAP score was 5 (IQR 6); median TSQM v.II global satisfaction score was 83.3 (IQR 25.0). According to the ADCT, 38.5-66.3% perceived their AD was 'in control', depending on the interpretability method used. Minimally clinically important difference (MCID) of ≥4 points for the DLQI and POEM was achieved respectively in N = 66 (84.6%) and N = 63 (78.8%) patients.CONCLUSION: When considering the favorable scores on other PROMs and the TSQM v. II, and comparing these to the relatively low percentage of patients perceiving control according to the ADCT, interpretability of eczema control still appears difficult. Treatment satisfaction in the studied cohort was high.
AB - BACKGROUND: Eczema control is a new construct to be measured in atopic dermatitis (AD).OBJECTIVES: Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 and 52 weeks.METHODS: Cross-sectional questionnaire study. Patients from the Dutch BioDay registry completed the Atopic Dermatitis Control Test (ADCT), Recap of Atopic Eczema (RECAP) and Treatment Satisfaction Questionnaire for Medication, Version II (TSQM v. II), along with other Patient Reported Outcome Measures (PROMs).RESULTS: 104/157 patients responded (response rate 66.2%). Median ADCT score was 4 (interquartile range [IQR] 5); median RECAP score was 5 (IQR 6); median TSQM v.II global satisfaction score was 83.3 (IQR 25.0). According to the ADCT, 38.5-66.3% perceived their AD was 'in control', depending on the interpretability method used. Minimally clinically important difference (MCID) of ≥4 points for the DLQI and POEM was achieved respectively in N = 66 (84.6%) and N = 63 (78.8%) patients.CONCLUSION: When considering the favorable scores on other PROMs and the TSQM v. II, and comparing these to the relatively low percentage of patients perceiving control according to the ADCT, interpretability of eczema control still appears difficult. Treatment satisfaction in the studied cohort was high.
KW - Atopic dermatitis
KW - atopic dermatitis control test
KW - dupilumab
KW - eczema control
KW - recap of atopic eczema
KW - treatment satisfaction questionnaire for medication
UR - http://www.scopus.com/inward/record.url?scp=85108282588&partnerID=8YFLogxK
U2 - 10.1080/09546634.2021.1937485
DO - 10.1080/09546634.2021.1937485
M3 - Article
C2 - 34151695
SN - 0954-6634
VL - 33
SP - 1986
EP - 1989
JO - The journal of dermatological treatment
JF - The journal of dermatological treatment
IS - 4
ER -